ATP-binding cassette transporter B1 (ABCB1) promotes chemoresistance in OSA because it can release doxorubicin, thereby reducing immunogenic cell death, drug-induced intracellular toxicity, and accumulation. Here, ABCB1 is linked to obstructive sleep apnea syndrome.